U.S. Markets close in 39 mins.

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
94.3378+0.9178 (+0.9824%)
As of 3:20PM EDT. Market open.
People also watch
ALXNVRTXREGNINCYBIIB

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415-506-6700
http://www.bmrn.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees2,293

Key Executives

NameTitlePayExercisedAge
Mr. Jean-Jacques Bienaimé MBAChairman & Chief Exec. Officer2.47M65.74M64
Mr. Daniel K. Spiegelman B.A., M.B.A.Chief Financial Officer and Exec. VP934.12k860.68k58
Dr. Robert A. Baffi Ph.D., MBAExec. VP of Technical Operations873.36kN/A62
Mr. Jeffrey Robert AjerChief Commercial Officer and Exec. VP864.5kN/A55
Dr. Henry J. Fuchs M.D., Ph.D.Pres of Worldwide R&D1.08M2.86M59
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.

Corporate Governance

BioMarin Pharmaceutical Inc.’s ISS Governance QualityScore as of September 1, 2017 is 4. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.